Clinical Characteristics of Refractory Myasthenia Gravis Patients

por Suh, Joome, Goldstein, Jonathan M., Nowak, Richard J.
Publicado 2013

Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management

por Zubair, Adeel S, Roy, Bhaskar, Baehring, Joachim M, Nowak, Richard J
Publicado 2022

Electronic health record derived-impact of COVID-19 on myasthenia gravis

por Roy, Bhaskar, Kovvuru, Sukanthi, Nalleballe, Krishna, Onteddu, Sanjeeva Reddy, Nowak, Richard J.
Publicado 2021

Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology

por Fichtner, Miriam L., Jiang, Ruoyi, Bourke, Aoibh, Nowak, Richard J., O’Connor, Kevin C.
Publicado 2020

Teleneurology during the COVID-19 pandemic: A step forward in modernizing medical care

por Roy, Bhaskar, Nowak, Richard J., Roda, Ricardo, Khokhar, Babar, Patwa, Huned S., Lloyd, Thomas, Rutkove, Seward B.
Publicado 2020

Novel Mutations in the CLCN1 Gene of Myotonia Congenita: 2 Case Reports

por Lakraj, Amanda Amrita, Miller, Geoffrey, Vortmeyer, Alexander O., Khokhar, Babar, Nowak, Richard J., DiCapua, Daniel B.
Publicado 2013

Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study

por Nowak, Richard J., Muppidi, Srikanth, Beydoun, Said R., O'Brien, Fanny L., Yountz, Marcus, Howard, James F.
Publicado 2020

Myasthenia gravis complement activity is independent of autoantibody titer and disease severity

por Fichtner, Miriam L., Hoarty, Michelle D., Vadysirisack, Douangsone D., Munro-Sheldon, Bailey, Nowak, Richard J., O’Connor, Kevin C.
Publicado 2022

A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy

por Ibrahim, Eiman Y., Munshani, Saira, Domenicano, Ilaria, Rodwin, Rozalyn, Nowak, Richard J., Pusztai, Lajos, Lustberg, Maryam, Ehrlich, Barbara E.
Publicado 2022

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study

por Jacob, Saiju, Murai, Hiroyuki, Utsugisawa, Kimiaki, Nowak, Richard J., Wiendl, Heinz, Fujita, Kenji P., O’Brien, Fanny, Howard, James F.
Publicado 2020

The Plasma Cell Infiltrate Populating the Muscle Tissue of Patients with Inclusion Body Myositis Features Distinct B Cell Receptor Repertoire Properties

por Jiang, Roy, Roy, Bhaskar, Wu, Qian, Mohanty, Subhasis, Nowak, Richard J., Shaw, Albert C., Kleinstein, Steven H., O’Connor, Kevin C.
Publicado 2023

Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis

por Masi, Gianvito, Pham, Minh C., Karatz, Tabitha, Oh, Sangwook, Payne, Aimee S., Nowak, Richard J., Howard, James F., Guptill, Jeffrey T., Juel, Vern C., O'Connor, Kevin C.
Publicado 2023

Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic

por Kovvuru, Sukanthi, Nalleballe, Krishna, Onteddu, Sanjeeva Reddy, Sharma, Rohan, Jasti, Madhu, Kapoor, Nidhi, Veerapaneni, Karthika, Yadala, Sisira, Dandu, Vasuki, Archer, Robert, Nowak, Richard J., Roy, Bhaskar
Publicado 2021

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

por Jacob, Saiju, Muppidi, Srikanth, Guidon, Amanda, Guptill, Jeffrey, Hehir, Michael, Howard, James F., Illa, Isabel, Mantegazza, Renato, Murai, Hiroyuki, Utsugisawa, Kimiaki, Vissing, John, Wiendl, Heinz, Nowak, Richard J.
Publicado 2020

Heterogeneity of Acetylcholine Receptor Autoantibody–Mediated Complement Activity in Patients With Myasthenia Gravis

por Obaid, Abeer H., Zografou, Chryssa, Vadysirisack, Douangsone D., Munro-Sheldon, Bailey, Fichtner, Miriam L., Roy, Bhaskar, Philbrick, William M., Bennett, Jeffrey L., Nowak, Richard J., O'Connor, Kevin C.
Publicado 2022

Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials

por Guptill, Jeffrey T., Benatar, Michael, Granit, Volkan, Habib, Ali A., Howard, James F., Barnett-Tapia, Carolina, Nowak, Richard J., Lee, Ikjae, Ruzhansky, Katherine, Dimachkie, Mazen M., Cutter, Gary R., Kaminski, Henry J.
Publicado 2023

MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity

por Yandamuri, Soumya S., Filipek, Beata, Obaid, Abeer H., Lele, Nikhil, Thurman, Joshua M., Makhani, Naila, Nowak, Richard J., Guo, Yong, Lucchinetti, Claudia F., Flanagan, Eoin P., Longbrake, Erin E., O’Connor, Kevin C.
Publicado 2023

Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis

por Fichtner, Miriam L., Vieni, Casey, Redler, Rachel L., Kolich, Ljuvica, Jiang, Ruoyi, Takata, Kazushiro, Stathopoulos, Panos, Suarez, Pablo A., Nowak, Richard J., Burden, Steven J., Ekiert, Damian C., O’Connor, Kevin C.
Publicado 2020

Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity

por Stathopoulos, Panos, Chastre, Anne, Waters, Patrick, Irani, Sarosh, Fichtner, Miriam L., Benotti, Erik S., Guthridge, Joel M., Seifert, Jennifer, Nowak, Richard J., Buckner, Jane H., Holers, V. Michael, James, Judith A., Hafler, David A., O’Connor, Kevin C.
Publicado 2019

Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients

por Takata, Kazushiro, Stathopoulos, Panos, Cao, Michelangelo, Mané-Damas, Marina, Fichtner, Miriam L., Benotti, Erik S., Jacobson, Leslie, Waters, Patrick, Irani, Sarosh R., Martinez-Martinez, Pilar, Beeson, David, Losen, Mario, Vincent, Angela, Nowak, Richard J., O’Connor, Kevin C.
Publicado 2019